Integral Health Asset Management LLC Purchases 75,000 Shares of Revolution Medicines, Inc. $RVMD

Integral Health Asset Management LLC lifted its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 23.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 400,000 shares of the company’s stock after purchasing an additional 75,000 shares during the quarter. Revolution Medicines accounts for 1.3% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 21st largest holding. Integral Health Asset Management LLC’s holdings in Revolution Medicines were worth $18,680,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. New York State Common Retirement Fund raised its holdings in Revolution Medicines by 39.3% during the third quarter. New York State Common Retirement Fund now owns 119,807 shares of the company’s stock worth $5,595,000 after buying an additional 33,821 shares during the last quarter. Raiffeisen Bank International AG acquired a new position in shares of Revolution Medicines during the third quarter valued at about $921,000. NEOS Investment Management LLC grew its holdings in shares of Revolution Medicines by 34.7% during the third quarter. NEOS Investment Management LLC now owns 126,921 shares of the company’s stock valued at $5,927,000 after buying an additional 32,694 shares during the last quarter. Tema Etfs LLC increased its position in shares of Revolution Medicines by 34.7% during the third quarter. Tema Etfs LLC now owns 126,921 shares of the company’s stock worth $5,927,000 after acquiring an additional 32,694 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC bought a new stake in shares of Revolution Medicines during the third quarter worth about $587,000. 94.34% of the stock is currently owned by institutional investors.

Insider Activity

In other Revolution Medicines news, CFO Jack Anders sold 10,000 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the transaction, the chief financial officer owned 108,065 shares of the company’s stock, valued at approximately $10,590,370. The trade was a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Margaret A. Horn sold 75,000 shares of the company’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total value of $7,542,000.00. Following the completion of the transaction, the chief operating officer owned 141,053 shares of the company’s stock, valued at $14,184,289.68. This trade represents a 34.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 149,792 shares of company stock worth $14,379,040 in the last quarter. 8.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Evercore raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, February 25th. Wolfe Research started coverage on Revolution Medicines in a report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price objective for the company. Benchmark reissued an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Revolution Medicines currently has a consensus rating of “Buy” and an average target price of $78.94.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $94.86 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The firm has a 50-day moving average of $102.88 and a 200-day moving average of $74.71. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $124.49. The company has a market cap of $18.80 billion, a P/E ratio of -16.05 and a beta of 0.99.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period last year, the firm posted ($1.12) EPS. Equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.